PL2294012T3 - Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit - Google Patents

Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit

Info

Publication number
PL2294012T3
PL2294012T3 PL09743658T PL09743658T PL2294012T3 PL 2294012 T3 PL2294012 T3 PL 2294012T3 PL 09743658 T PL09743658 T PL 09743658T PL 09743658 T PL09743658 T PL 09743658T PL 2294012 T3 PL2294012 T3 PL 2294012T3
Authority
PL
Poland
Prior art keywords
bowel
antibiotic
administration
treatment
cleanser
Prior art date
Application number
PL09743658T
Other languages
English (en)
Inventor
Lorin Johnson
William Forbes
Stephana Patton
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of PL2294012T3 publication Critical patent/PL2294012T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL09743658T 2008-05-07 2009-05-07 Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit PL2294012T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5134108P 2008-05-07 2008-05-07
EP09743658.8A EP2294012B1 (en) 2008-05-07 2009-05-07 Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
PCT/US2009/043138 WO2009137672A1 (en) 2008-05-07 2009-05-07 Methods of treating bowel disease by administering a bowel cleanser and an antibiotic

Publications (1)

Publication Number Publication Date
PL2294012T3 true PL2294012T3 (pl) 2014-12-31

Family

ID=41265004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09743658T PL2294012T3 (pl) 2008-05-07 2009-05-07 Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit

Country Status (12)

Country Link
US (2) US20090324736A1 (pl)
EP (1) EP2294012B1 (pl)
JP (1) JP5752032B2 (pl)
AU (1) AU2009244190B2 (pl)
CA (1) CA2723752A1 (pl)
DK (1) DK2294012T3 (pl)
ES (1) ES2509892T3 (pl)
HR (1) HRP20140939T1 (pl)
PL (1) PL2294012T3 (pl)
PT (1) PT2294012E (pl)
SI (1) SI2294012T1 (pl)
WO (1) WO2009137672A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2009108730A2 (en) 2008-02-25 2009-09-03 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
RU2012126084A (ru) * 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US8532349B2 (en) 2010-02-02 2013-09-10 Omnivision Technologies, Inc. Encapsulated image acquisition devices having on-board data storage, and systems, kits, and methods therefor
ES2951828T3 (es) 2010-09-23 2023-10-25 Leading Biosciences Inc Administración de inhibidores de serina proteasa al estómago
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
EP2874624B8 (en) * 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
KR20170098980A (ko) 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
EP2895169A4 (en) * 2012-09-12 2016-02-24 Salix Pharmaceuticals Inc METHODS OF ADMINISTERING RIFAXIMINE WITHOUT PRODUCING ANTIBIOTIC RESISTANCE
EP2894982A4 (en) * 2012-09-13 2016-06-22 Salix Pharmaceuticals Inc METHODS OF IMPROVING LONG-TERM SURVIVAL AND REDUCING HOSPITAL RE-EMISSION RATES IN PATIENTS WITH HEPATIC ENCEPHALOPATHY
CA2903283C (en) 2013-03-15 2023-09-05 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
CN105307654B (zh) * 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 用于治疗微生物区系相关的精神病况和疾病的组合物和方法
CA2912712A1 (en) * 2013-05-17 2014-11-20 Salix Pharmaceuticals, Inc. Methods of using rifaximin in position emission tomography (pet) scans
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
KR101423005B1 (ko) 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
US9387199B2 (en) * 2013-11-12 2016-07-12 University Of Virginia Patent Foundation Compositions and methods for treating clostridium infection and preventing recurrence of infection
EP3122349B1 (en) 2014-03-25 2021-12-22 Leading Biosciences, Inc. Compositions for the treatment of autodigestion
EA201692106A1 (ru) 2014-04-29 2017-04-28 КОЛОНАРИКОНСЕПТС ЭлЭлСи Пищевые продукты, системы, способы и наборы для замены электролитов
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
HK1247283A1 (zh) 2015-03-02 2018-09-21 科罗纳里康赛普茨有限责任公司 用於peg代谢物及peg分解产物检测的化合物及方法
HRP20200432T1 (hr) 2015-04-02 2020-06-12 Theravance Biopharma R&D Ip, Llc Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva
KR102619907B1 (ko) * 2015-08-17 2024-01-02 서화수 가축설사 치료용 복합제 조성물
CA3010865A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
PL3416627T3 (pl) * 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
EP3737380A4 (en) * 2018-01-11 2021-09-29 Meritage Pharma, Inc. STABLE CORTICOSTEROID COMPOSITIONS
WO2019178652A1 (en) * 2018-03-23 2019-09-26 Borody Thomas J Compositions and methods for treating inflammatory bowel disease and fusobacteria-caused or related diseases and conditions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3363997A (en) 1958-12-22 1968-01-16 Monsanto Co Composition of matter and process
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
AU6196786A (en) 1985-08-01 1987-03-05 Braintree Laboratories Inc. Low-sodium laxative and lavage formulation
DE3889547T2 (de) 1987-12-24 1994-11-17 Borody Thomas J Orthostatische waschlösungen.
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
DK1017404T3 (da) * 1997-09-26 2004-11-01 Celltech Pharma Europ Ltd Farmaceutisk sammensætning til behandling af inflammatorisk tarmsygdom
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
AU2003260736B8 (en) * 2002-08-26 2009-04-23 S.L.A. Pharma Ag A pharmaceutical composition
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7687075B2 (en) * 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
AU2006244112B2 (en) * 2005-05-06 2011-02-17 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
ES2747259T3 (es) * 2006-03-09 2020-03-10 Salix Pharmaceuticals Inc Preparación anti-disfunción rectal de rifaximina
US20100069421A1 (en) * 2006-08-02 2010-03-18 Doug Bettenhausen Compositions and methods for the treatment of radiation proctosigmoitis
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2201372A4 (en) * 2007-10-17 2010-11-10 Salix Pharmaceuticals Ltd NEW THERAPEUTIC TARGET MOLECULES IN STOMACH DISEASES
WO2019023892A1 (en) 2017-07-31 2019-02-07 SZ DJI Technology Co., Ltd. MOTION-BASED IMPRESSION CORRECTION IN POINT CLOUDS
US11960008B2 (en) 2018-05-17 2024-04-16 Cmos Sensor, Inc. Method and system for pseudo 3D mapping in robotic applications
KR102382079B1 (ko) 2020-02-11 2022-03-31 효성중공업 주식회사 에어갭 조절장치
US11963008B2 (en) 2020-11-25 2024-04-16 Truist Bank Geolocation-based notifications using relationships in separate systems

Also Published As

Publication number Publication date
US20090324736A1 (en) 2009-12-31
EP2294012A4 (en) 2011-10-26
HK1156293A1 (en) 2012-06-08
PT2294012E (pt) 2014-10-15
HRP20140939T1 (hr) 2014-11-21
ES2509892T3 (es) 2014-10-20
EP2294012B1 (en) 2014-07-09
JP5752032B2 (ja) 2015-07-22
WO2009137672A1 (en) 2009-11-12
JP2011519952A (ja) 2011-07-14
AU2009244190A1 (en) 2009-11-12
SI2294012T1 (sl) 2014-11-28
DK2294012T3 (da) 2014-10-06
AU2009244190B2 (en) 2016-02-25
EP2294012A1 (en) 2011-03-16
US20130164384A1 (en) 2013-06-27
CA2723752A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
SI2294012T1 (sl) Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
IL192299A0 (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
IL220613B (en) Use of antibiotics and a probiotic formulation in the preparation of a drug for the treatment of inflammatory bowel disease
GB2455238B (en) Patient monitor
EP1980271A4 (en) MEDICINE FOR TRANSNASAL ADMINISTRATION
EP2008572A4 (en) CAPSULE MEDICAL DEVICE
GB0803072D0 (en) Solid pharmaceutical and vaccien dose
EP2026712A4 (en) HYBRID MEDICINE PRODUCTS FROM SYNTHETIC / BIOLOGICAL TISSUE MATERIAL
ZA200904756B (en) Methods of vaccine administration
IL236360A0 (en) Inhalable medicine
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
GB201108964D0 (en) Medicament and method of diagnosis
EP2087831A4 (en) MEDICAL DEVICE OF CAPSULE TYPE
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
GB0911061D0 (en) Tablet formulation
GB0709092D0 (en) Diagnosis and method of disease
GB0625783D0 (en) Medicament
IL195618A0 (en) Drug administration methods
EP2081480A4 (en) MEDICINE PRODUCT OF THE CAPSULE TYPE
EP2210878A4 (en) THERAPEUTIC AGENT AGAINST TRPV1-MEDIATED DISEASES
GB0615064D0 (en) Medicament
GB0623740D0 (en) Treatment of disease
GB0621308D0 (en) An implement for administering medicine
GB0615814D0 (en) Medicament